Activation of liver X receptors (LXRs) with synthetic agonists promotes reverse cholesterol transport and protects against atherosclerosis in mouse models. Most synthetic LXR agonists also cause marked hypertriglyceridemia by inducing the expression of SREBP1c and downstream genes that drive fatty acid biosynthesis. Recent studies demonstrated that desmosterol, an intermediate in the cholesterol biosynthetic pathway that suppresses SREBP processing by binding to SCAP, also binds and activates LXRs and is the most abundant LXR ligand in macrophage foam cells. Here, we explore the potential of increasing endogenous desmosterol production or mimicking its activity as a means of inducing LXR activity while simultaneously suppressing SREBP1c induced hypertriglyceridemia. Unexpectedly, while desmosterol strongly activated LXR target genes and suppressed SREBP pathways in mouse and human macrophages, it had almost no activity in mouse or human hepatocytes in vitro. We further demonstrate that sterol-based selective modulators of LXRs have biochemical and transcriptional properties predicted of desmosterol mimetics and selectively regulate LXR function in macrophages in vitro and in vivo. These studies thereby reveal cell-specific discrimination of endogenous and synthetic regulators of LXRs and SREBPs, providing a molecular basis for dissociation of LXR functions in macrophages from those in liver that lead to hypertriglyceridemia.
INTRODUCTION
Although improvements in the prevention and treatment of cardiovascular disease (CVD) over the last decade have contributed to a significant reduction in the burden of CVD, it still accounts for over a third of all deaths in the United States and worldwide each year (1). In fact, more people die each year secondary to CVD than any other cause, with coronary heart disease and stroke representing the majority of cases (2) . Increased apolipoprotein B-100 (ApoB)associated lipid species, namely LDL cholesterol (LDL-C), remains one of the best-appreciated risk factors for atherosclerotic heart disease. Accordingly, reduction of LDL-C through the use of statins or recently developed antibodies directed against proprotein convertase subtilisin/kexin type 9 (PCSK9) represents one of the mainstays of preventive therapy (3, 4) . However, myocardial infarction and stroke still occur in a subset of individuals despite cholesterol lowering, and therapies directed at additional targets are of potential clinical benefit.
Macrophages are key cellular players in the initiation and progression of atherosclerosis through their roles in uptake of modified lipoproteins in the artery wall, production of inflammatory mediators, and secretion of metalloproteases that contribute to plaque instability (5) (6) (7) (8) . A subset of macrophages within atherosclerotic lesions are characterized by massive accumulation of cholesterol esters in lipid droplets, resulting in a 'foam cell' phenotype indicative of a failure of normal cholesterol homeostasis. Given their central role in integrating both cholesterol homeostasis and inflammatory signaling in macrophages, the liver X-receptors (LXR) represent logical targets for pharmacologic intervention in atherosclerosis (9) (10) (11) . LXR activation is known to promote cholesterol efflux in macrophages by activation of ATP-binding cassette transporter A1 and G1 (ABCA1/ ABCG1) (12, 13) while also repressing the proinflammatory products of NF-κB signaling (14) . Stimulation of cholesterol efflux in macrophages and other cell types contributes to overall functions of LXRs in mediating reverse cholesterol transport from peripheral cells to the liver for biliary secretion (15, 16) .
Consistent with these homeostatic functions, deletion of LXRs either at the whole body level or within the hematopoietic compartment results in accelerated atherosclerosis in mouse models (17, 18) . Conversely, administration of potent synthetic LXR agonists, such as GW3965, inhibits the development of atherosclerosis in these models (19) (20) (21) . However, most synthetic agonists of LXR have also been found to strongly activate SREBP1c and downstream genes involved in fatty acid biosynthesis, including fatty acid synthase (FAS), that subsequently lead to increased serum cholesterol and triglyceride levels (22, 23) . Thus, while activating LXR has positive effects in the prevention of atherosclerosis in terms of enhancing reverse cholesterol transport and suppression of pro-inflammatory pathways, the negative aspect of hypertriglyceridemia and fatty liver -a product of SREBP activation -has prevented synthetic LXR agonists from being clinically useful therapeutics. Empiric efforts to develop 'dissociated' LXR agonists that retain the ability to activate LXRs but do not induce hypertriglyceridemia have been partially successful (24) (25) (26) (27) , but underlying mechanisms are poorly understood.
LXR activity is normally induced under conditions of cholesterol excess in a manner that is reciprocal to coordinate inhibition of the processing of the SREBP transcription factors. LXRs do not sense cholesterol directly, but are instead positively regulated by oxysterols and intermediates in the cholesterol biosynthetic pathway (28) (29) (30) . In contrast to most synthetic LXR agonists, natural LXR agonists also suppress processing of the SREBP proteins (31) . In the case of oxysterols, such as 25-hydroxy cholesterol, inhibition is mediated through interactions with the INSIG proteins that prevent trafficking of SREBPs to the Golgi for proteolytic activation (32) .
The cholesterol biosynthetic intermediate desmosterol was first noted to be an endogenous LXR-activating ligand in studies of plant sterols and sterol intermediates in the cholesterol biosynthetic pathway (30) . In contrast to oxysterols, desmosterol most likely suppresses SREBP processing by interacting with SCAP to retain the SREBPs in the endoplasmic reticulum (31) .
In a lipidomic analysis of murine macrophage foam cells and human atherosclerotic plaques, desmosterol was found to be the most abundant endogenous LXR activator (33) . The accumulation of desmosterol in macrophage foam cells was correlated with downregulation of Dhcr24, which encodes the 24-dehydroxycholesterol reductase enzyme that converts desmosterol to cholesterol (Figure 1A) . Notably, treatment of macrophages with increasing concentrations of desmosterol led to coordinate increases in LXR-dependent pathways and suppression of SREPB-pathways. As a consequence, genes involved in cholesterol efflux were induced, while genes involved in cholesterol and fatty acid synthesis were downregulated (33) .
These findings confirmed the prediction that desmosterol could balance lipid homeostasis via reciprocal actions on LXR and SREBP activities (30) .
These observations raised the questions of whether the desmosterol pathway operates in other cell types and whether it would be possible to activate this pathway, or mimic it, as a therapeutic strategy. Studies in mouse macrophages pointed to downregulation of Dhcr24 as being the key event leading to accumulation of desmosterol (33) . One straightforward strategy would thus be to inhibit DHCR24 activity. Remarkably, this was first achieved more than 50 years ago following the identification of triparanol (also known as mer-29) as a potent inhibitor of DHCR24. Administration of triparanol to hypercholesterolemic human subjects led to marked reductions in serum cholesterol and corresponding rises in circulating desmosterol (34, 35) .
However, triparanol was rapidly withdrawn from the market after reports of severe cataracts and alopecia (36) (37) (38) and there is no evidence whether there was an impact on the development of cardiovascular diseases. While there are dermatologic manifestations of desmosterolosis, it is unknown if the extent of alopecia or development of cataracts is specifically related to increased circulating desmosterol or potentially an off-target effect of triparanol (39) .
Here, we investigate the potential to modulate and mimic the desmosterol pathway in vivo and in vitro as a means of coordinately regulating the LXR and SREBP pathways. To modulate the desmosterol pathway in vivo, we developed potent and specific anti-sense oligonucleotides (ASOs) that reduce Dhcr24 expression in liver by more than 80%.
Unexpectedly, while this treatment resulted in significant increases in endogenous desmosterol, no significant changes in LXR or SREBP target genes were observed in the liver. To mimic the desmosterol pathway, we demonstrate that previously reported selective LXR modulators DMHCA (27) and MePipHCA (40) have properties of synthetic desmosterol mimetics. While desmosterol, DMHCA and MePipHCA coordinately regulate the LXR and SREBP pathways in primary mouse and human macrophages, they exhibited very little effect on gene expression in primary mouse and human hepatocytes. The differential effects of DMHCA and MePipHCA on LXR and SREBP target genes in macrophages and hepatocytes are also observed in vivo.
Remarkably, LXR target genes are activated in Kupffer cells in response to DMHCA, in contrast to liver as a whole. In concert, these findings suggest a molecular basis for dissociation of LXR functions in macrophages and hepatocytes that would enable retention of anti-atherogenic properties without promoting hypertriglyceridemia.
RESULTS

Blockade of DHCR24 using gene-specific ASO leads to increased endogenous desmosterol
without potentiating LXR-mediated target genes.
To modulate the endogenous desmosterol pathway for coordinate regulation of LXR and SREBP target genes in vivo, we developed antisense oligonucleotides (ASOs) specific to 24dehydrocholesterol reductase (DHCR24). Based on the effects of inhibition of DHCR24 by triparanol and genetic deficiency of Dhcr24, we hypothesized that reduction of Dhcr24 expression would lead to increased desmosterol levels and corresponding changes in LXR-and SREBP-dependent gene expression ( Figure 1A) . Out of more than fifty potential Dhcr24 specific ASOs developed and initially assayed (data not shown) we tested four of the most active ASOs in plated thioglycolate elicited macrophages (TGEMs) (Figure 1B) . After 48 hours of exposure to ASO, Dhcr24 gene expression as assessed through quantitative real-time polymerase chain reaction (qRT-PCR) was less than a quarter of scramble control (SCR) with four separate Dhcr24-specific ASOs (ION-599805, ION-599830, ION-599832 and ION-599847, hereafter referred to as 805, 830, 832 and 847, respectively). Dhcr24 gene expression was also unchanged by a negative control MMP9 ASO compared to the SCR-treated cells. We then aimed to use these ASOs to reduce Dhcr24 expression in C57Bl/6 mice.
We delivered control (SCR) ASO and two separate DHCR24-specific ASO to six mice per group via biweekly intraperitoneal (i.p.) injections over a three-week period (Supplemental Figure 1A) . The treatment regimen was well tolerated in all study groups with expected weight gain and no difference in body weights at the termination of the study (Supplemental Figure   1B ). Following three weeks of treatment, hepatic expression of Dhcr24 was markedly reduced in both cohorts of Dhcr24 ASO treated animals as compared with SCR control (15% and 25% vs. SCR control for 805 and 873, respectively, p < 0.001) ( Figure 1C ). This was mirrored by a substantial reduction in DHCR24 gene product as examined by Western immunoblot analysis of liver extract (Figure 1D) . Concomitant with this reduction of Dhcr24 gene expression and protein, circulating plasma desmosterol increased by 10-fold after treatment with Dhcr24 ASO (0.38 ± 0.04 µM, 3.97 ± 0.65 µM, 2.27 ± 0.50 µM for SCR, 805 and 873, respectively) as measured by LC-MS ( Figure 1E ). In addition, hepatic desmosterol levels increased after Dhcr24 ASO treatment (1.87 ± 0.53 ng/mg, 12.50 ± 2.01 ng/mg, 16.23 ± 4.34 ng/mg for SCR, 805 and 873, respectively) attributable mainly to increases in free rather than esterified desmosterol ( Figure 1E) . Surprisingly, despite these increases in circulating and hepatic desmosterol there were no observed alterations in the expression of the key hepatic LXR-target genes ATP-binding cassette transporter subfamily A, member 1 (Abac1), ATP-binding cassette transporter subfamily G, member 5 (Abcg5) or ATP-binding cassette transporter subfamily G, member 8 (Abcg8) in Dhcr24 ASO treated animals versus SCR control ( Figure 1C) . Nor were there differences in the hepatic expression of SREBP-target genes (Figure 1C) .
In a second experimental paradigm, we performed 1 week of subcutaneous (s.q.) ASO treatment in C57BL/6 mice who received thioglycolate 4 days prior to study end. Both liver and TGEMs showed a reduction in Dhcr24 gene expression, although macrophages responded less robustly than liver (95% and 73% reduction in liver and macrophage of Dhcr24 ASO vs SCR control treated animals, respectively) (Supplemental Figure 1C) . As in the case of liver, the major LXR-target genes Abca1 and Abcg1 were not significantly modulated (p= ns for both, Dhcr24 ASO vs SCR ASO) despite increased desmosterol concentrations in plasma, liver and macrophage (Supplemental Figure 1D ). Taken together, these data show that while Dhcr24specific ASOs reduced hepatic and macrophage expression of Dhcr24 mRNA and protein leading to increased levels of cellular and circulating desmosterol, they did not lead to activation of LXR-target genes or suppression of SREBP target genes.
Cell-type specific effect of desmosterol in macrophage as compared to hepatocytes
The lack of an effect of knockdown of Dhcr24 in liver on LXR-or SREBP target genes despite a significant increase in hepatic desmosterol raised the questions of whether desmosterol reached sufficient intracellular concentrations to be active and/or whether the desmosterol pathway is utilized in the liver. To directly compare responses of macrophages and hepatocytes to desmosterol, we evaluated the expression of Dhcr24 and Abca1 in plated TGEMs and DHCR24 and ABCA1 in HepG2 cells treated with increasing concentrations of desmosterol and the synthetic LXR-ligand T0901317 (Figure 2A) . Whereas treatment with T0901317 resulted in an increase of Abca1 expression in TGEMs (19.05 ± 3.86, p < 0.01 for 1 µM T0901317 relative to vehicle) and ABCA1 expression in HepG2 (1.80 ± 0.30, p < 0.01 for 1 µM T0901317 relative to vehicle) cells, this LXR-target gene was up-regulated only in TGEMs (8.51 ± 1.40, p < 0.01 relative to vehicle) but not HepG2 cells after treatment with 10 µM desmosterol. In addition, while there was no effect of T0901317 on the suppression of the SREBP-target gene Dhcr24 in either cell type, treatment with 10 µM desmosterol resulted in a marked down-regulation of Dhcr24 (0.19 ± 0.08, p < 0.01 relative to vehicle) solely in TGEMs (Figure 2A) .
To further explore the specific LXR-and SREBP-dependent gene responses to desmosterol we performed qRT-PCR analysis in primary macrophages and primary hepatocytes from both mice and humans (Figure 2B and 2C) . Treatment of TGEMs with 10 µM desmosterol resulted in an increase in the LXR-responsive gene Abca1 (8.06 ± 1.80, p < 0.05 relative to vehicle) and a decrease in Dhcr24 (0.19 ± 0.04, p < 0.05 relative to vehicle) without subsequent activation of the SREBP-responsive gene fatty acid synthase (Fasn), whereas it had no effect in primary mouse hepatocytes ( Figure 2B) . In contrast, treatment of cells with the synthetic selective LXR ligand GW3965 resulted in increased levels of Abca1 (22.77 ± 4.62, p < 0.05 relative to vehicle) and Fasn (7.13 ± 1.64, p < 0.05 relative to vehicle) mRNA in both macrophages and hepatocytes (5.58 ± 1.28, p < 0.05 and 3.64 ± 0.34, p < 0.05 for Abca1 and Fasn, respectively) ( Figure 2B) . The LXR and SREBP-target gene expression changes induced by desmosterol and GW3965 in mouse macrophages and hepatocytes were fully recapitulated in human monocyte-derived macrophages (HMDM) and primary hepatocytes ( Figure 2C) .
Collectively, these data suggest that while desmosterol effectively leads to a dose-dependent increase in LXR target genes without inducing SREBP-target genes as is seen for synthetic selective LXR ligands in both human and mouse macrophages, these effects are largely absent in hepatocytes.
Synthetic desmosterol mimetics exhibit a cell-type specific LXR activation profile similar to desmosterol
Appreciating the differential LXR and SREBP target gene response in macrophages and hepatocytes of desmosterol as compared to conventional LXR ligands (e.g., GW3965, T0901317), we sought synthetic compounds that might represent desmosterol mimetics. Such molecules by definition would function as agonists of LXRs and antagonists of SREBP processing by interacting with SCAP. While the chemical structures of GW3965 and T0901317 are vastly dissimilar to desmosterol (Figure 3A) , DMHCA, a previously reported synthetic dissociated LXR agonist with anti-atherosclerotic potential, retains much of the same desmosterol chemical backbone (24, 26, 27) . In TGEMs, DMHCA not only activates LXR target genes such as Abca1 and fails to induce Fasn expression, as previously reported, but also strongly represses the SREBP target gene Dhcr24 (Figure 3B ). This activity profile is thus consistent with that of a desmosterol mimetic. In addition, we evaluated recently developed derivatives of DMHCA, exemplified by MePipHCA, which we recently reported as a dissociated LXR agonist that inhibits inflammation in models of traumatic brain injury and inflammatory bowel disease (41) . Similar to DMHCA, MePipHCA not only activated the LXR target genes in macrophages, but also strongly suppressed Dhcr24 expression ( Figure 3C) . We also observed that, in contrast to T0901317, DMHCA and MePipHCA did not cause lipid accumulation in HepG2 cells after 72 hour treatment (Figure 3D) , consistent with a lack of an effect of DMHCA and MePipHCA on SREBP1c expression and lipid biogenesis.
Whole transcriptome assessment of desmosterol mimetics
Having appreciated the cell-type specific characteristics of desmosterol signaling, the similarities shared with DMHCA, especially in terms of the dissociation of LXR and SREBP pathway regulation, and promise of the structurally related mimetic MePipHCA, we conducted an unbiased, whole transcriptome comparison of these ligands with the conventional LXRligands GW3965 and T0901317 using RNA-sequencing (RNA-Seq) analysis. We began by treating plated TGEM and mouse primary hepatocytes with desmosterol (10 µM), DMHCA (1 MePipHCA assorting itself distinctly along the first two eigenvectors ( Figure 4D) . The divergence of MePipHCA for upregulated genes is partly driven by its activation of several genes that have functional annotations associated with the "Response to unfolded protein" pathway in GO term analysis. Of note, this pathway is also activated by 25-hydroxy cholesterol in macrophages (42) .
We observed similar differences in the transcriptional responses of macrophages and hepatocytes in our unbiased, whole transcriptome RNA-Seq analysis of human cells. First we compared the global response of up-and down-regulated genes in response to these ligands in both HMDM and human primary hepatocytes ( Figure 5A) . Notably, and similar to our studies in While the vast majority of genes that were up-and down-regulated by desmosterol, DMHCA and T0901317 were shared in mouse and human macrophages, we also noted certain genes that were differentially regulated ( Figure 5D ). While the roles of many of these genes in lipid homeostasis and regulation of inflammation remain unappreciated, we did observe differences in key genes such as the nuclear receptors LXRα (NR1H3) and retinoic acid receptor (RARA), both differentially induced in HMDM, and several regulators of lipid metabolism such as fatty acid desaturase (FADS1), 7-dehydrocholesterol reductase (DHCR7) and farnesyldiphosphate farnyltransferase (FDFT1), all suppressed in HMDM compared to mouse TGEM.
The macrophage-specific induction of LXR-response genes without potentiation of SREBP pathways with synthetic desmosterol mimetics is recapitulated in vivo.
We then sought to examine if the cell-type specific effects observed in plated macrophages and hepatocytes in response to desmosterol and desmosterol mimetics (DMHCA and MePipHCA) were recapitulated in an in vivo model. We treated mice with thioglycollate by i.p. injection four days prior to treatment with compounds in order to elicit macrophage accumulation in the peritoneum. DMHCA, MePipHCA and T0901317 (50 mg/kg) were then given by i.p. injection 6 hours and 16 hours before peritoneal macrophages and whole liver were isolated and prepared for gene expression analysis. Gene expression of the LXR-responsive gene Although responses to DMHCA and MePipHCA were minimal or absent in intact liver, it was of interest to determine whether Kupffer cells, the resident macrophage population of the liver, exhibited similar responses to those observed in elicited peritoneal macrophages. To address this question, we treated mice with vehicle, DMHCA or T0901317 by i.p. injection, and 12h following injection Kupffer cells were purified by fluorescence activated cell sorting with target cells identified by CD45 + F4/80 + CD11b int Tim4 + CD146 -CD31 -. As in the case of peritoneal macrophages, DMHCA was shown to selectively activate LXR-responsive genes in Kupffer cells (Abca1) but not whole liver (Abcg5) (Figure 6B ). Whereas DMHCA had no effect on SREBPresponsive genes in either tissue compared to the dual activation of LXR-and SREBPresponsive genes by T0901317. These results indicate that these sterol-based synthetic LXR agonists (DMHCA and MePipHCA) appear to act preferentially in macrophages (and Kupffer cells) as compared to hepatocytes in vivo and, unlike T0901317, without potentiating SREBP1responsive genes.
DISCUSSION
Despite their key roles at the intersection of lipid metabolism and inflammation, the promise of LXRs as pharmacologic targets for the prevention and treatment of atherosclerotic heart disease has been limited by the difficulty of decoupling beneficial effects from activation of SREBP1-dependent pathways. Development of selective LXR modulators has been challenging in part because there are few evident rationale approaches for achieving this goal. A leading strategy has been to synthesize molecules that preferentially activate LXRβ, based on evidence for a dominant role of LXRα in driving SREBP1c expression and fatty acid biosynthesis in mouse liver (9, 19, 41, 42) . However, a recent evaluation of a prototypic LXRβ-selective synthetic ligand demonstrated that in addition to induction of LXR target genes in human blood cells and inhibition of atherosclerosis in mouse models, it retained the ability to increase circulating triglyceride levels and hepatic triglycerides in human subjects (43) .
Here, we have explored an alternative strategy that is based on the observation that most or all physiologic LXR agonists are also inhibitors of SREBP processing, either by binding to INSIGs (e.g., oxysterols) or SCAP (desmosterol). In contrast to synthetic agonists that selectively target LXRs, such endogenous ligands would be expected to activate genes involved in reduction of cellular cholesterol but have an attenuated effect on fatty acid biosynthesis due to inhibitory effects on processing of SREBP1c. We thus sought to test the hypothesis that raising endogenous levels of LXR agonists or mimicking their activity would have these effects.
Our initial in vivo approach was to increase intracellular concentrations of desmosterol by specifically reducing the activity of DHCR24 using antisense oligonucleotide technology.
Unexpectedly, despite a marked elevation in hepatic and circulating desmosterol levels after treatment with Dhcr24-specific ASOs, we failed to observe concomitant activation of key LXRresponse genes in liver or macrophages. One possible interpretation of this result is that, while significantly elevated, desmosterol did not reach intracellular concentrations required to activate LXRs. This hypothesis was supported by our observation that 10 µM desmosterol significantly elevated LXR-target genes in TGEM but not 1 µM desmosterol (Figure 2A) . In addition, serum desmosterol levels of Dhcr24 ASO treated mice were less than 20% of those observed in human subjects treated with triparanol or in the rare genetic disease of desmosterolosis (39, 44, 45) .
Additionally, although our studies were short term (1-3 weeks), we did not observe evidence of alopecia characteristic of Dhcr24 knockout mice and humans treated with triparanol in the animals treated with Dhcr24 ASO (unpublished observation). We conclude that raising endogenous desmosterol levels by reducing Dhcr24 expression using ASOs is unlikely to be an effective strategy for activation of LXRs in vivo.
Given the inability to modulate the LXR axis by increasing endogenous desmosterol concentrations with Dhcr24 ASO, we sought to specifically assess the desmosterol pathway in hepatocytes. Unexpectedly, we observed that concentrations of desmosterol that effectively activated LXR-responsive genes and suppressed SREBP-responsive genes in macrophages had little or no effect on these genes in mouse and human hepatocytes. Thus, these studies provide evidence for a cell-autonomous mechanism enabling cell-specific discrimination of an endogenous LXR ligand that confers selective activation of LXR target genes in macrophages.
Based on these findings, we characterized DMHCA, an empirically developed LXR agonist that exhibits anti-atherosclerotic activity without causing substantial hypertriglyceridemia in mice (24) . Importantly, unlike conventional LXR agonists such as GW3965 and T090137, DMHCA is structurally related to desmosterol, raising the possibility that it functions as a desmosterol mimetic. Consistent with this possibility, DMHCA coordinately induced LXR target genes and repressed SREBP target genes. We therefore In addition to regulating the LXR/SREBP pathways, desmosterol was previously shown to inhibit inflammatory responses in macrophages, consistent with the actions of other LXR agonists (33) . Although not evaluated for anti-inflammatory effects in these studies, we recently reported that MePipHCA significantly reduced disease severity and inflammatory markers in models of inflammatory bowel disease and traumatic brain injury without causing lipid accumulation in liver (40) . A limitation of the current synthetic desmosterol mimetics is a relatively poor pharmacokinetic profile, requiring large doses for in vivo efficacy. Therefore, it is likely that substantial additional effort will be required to develop more drug-like molecules.
A major new and exciting question is the basis for cell-specific discrimination of desmosterol that confers preferential activity in macrophages. It is unlikely to be simple conversion of desmosterol to cholesterol or another LXR agonist because similar activities were observed for the synthetic agonists DMHCA and MePipHCA. A cell autonomous basis for this discrimination is strongly supported by the finding that Kupffer cells in the liver robustly respond to DMHCA, while surrounding hepatocytes do not. The mechanism presumably distinguishes between desmosterol/desmosterol mimetics and oxysterols, given the genetic evidence that 24 hydroxycholesterol, 25 hydroxycholesterol and 27 hydroxycholesterol are endogenous agonists of LXRs in the liver (46) . We speculate that proteins involved in the intracellular transport of desmosterol/desmosterol mimetics restrict their access to SCAP and SREBPs in hepatocytes but not macrophages. Further understanding of the mechanism underlying differential actions of desmosterol in macrophages and hepatocytes thus remains an important future goal. 
MATERIALS & METHODS
Reagents
In vivo injection of LXR agonists and purification of Kupffer cells. Mice were treated by i.p.
injection with 50 mg/kg of DMHCA or T0901317 dissolved in 50:50 ethanol and M-pyrol at a concentration of 50 mg/ml. 12 hours later, mice were humanely euthanized by exposure to CO 2 and whole liver pieces saved and liver non-parenchymal cells processed for fluorescence activated cell sorting of Kupffer cells, with modifications from published methodology (47, 48) .
(Refer to supplement for additional details).
RNA Isolation and quantitative polymerase chain reaction. Total RNA was isolated with
Trizol Reagent (Life Technologies) and Direct-zol RNA Spin Columns (Zymo Research, Irvine, CA). Total RNA was used for either first strand cDNA synthesis with SuperScriptIII (Life Technologies) or for RNA-sequencing (RNA-seq) library preparation. Real-time PCR reactions were prepared in 96-well plates using iTaq SYBR Green Supermix (BioRad, Hercules, CA) and performed on the StepOnePlus Quantitative Polymerase Chain Reaction Platform (Life Technologies) (Refer to supplement for additional details).
RNA-Sequencing Library Preparation. Please see supplement for details. Briefly, polyA
RNA was used for first-strand cDNA synthesis. Second strand synthesis was carried out using deoxy-UTP. Follwing end-repair the product was then incubated with EDAC SeraMag SpeedBeads and eluted with EB (Zymo). This was followed by dA-tailing, unique barcode adapter ligation and second strand digestion with UDG (Enzymatics). CKB  LAT  CXCL2  IER3  FZD1  CYP27A1  FAM213B  GYPC  ATF3  JDP2  CTSK  EMP1  DUSP2  TSC22D1  PDGFB  TMEMM5B  FGL2  RGL1  CAMK1  TGFBI  ACOT7  TMEM256  CRIP1  ISOC2  OAZ2  EVL  GALM  LACC1  SEPP1  HES6  LPAR5  NUDT8  IGFBP4  IL7R  SLC38A2  SLC29A1  NR1H3   TIFAB  CXCL2  ATP1B1  TMEM97  HMGCS1  TM7SF2  C14ORF1  MVK  SC5D  HSD17B7  SQLE  HMGCR  CYP51A1  FDFT1  ACAT2  EBP  FDPS  DHCR7  INSIG1  MSMO1  MVD  LDLR  FADS2  FADS1  LPIN1  ALDOC  ACLY  AACS  LSS  DHCR24  PCYT2  NSDHL  MMAB  ACSS2  STARD4  TSC22D3  TUBA1A  VWF  PANK3  FASN  SCD  ABCG1  SMPDL3A  ABCA1  SDC3  SREBF1  CD82  CDCA7L  ARL4C  MYLIP  NEURL2  PLTP  LPCAT3  CFP  CXCR4  TRPV4  NR1H3  SLC29A1  ACVRL1  DHRS3  ABCD1  RARA  HPSE  COQ2   PLIN2  SEMA6B  PTGER2  TFPI  RAB20  IL1RN  TMCC3  PLAUR  HK2  SLC2A1  CD300A  EXT1  HPSE  GBP2  STOM  TNFRSF21  TRPV4  S1PR1  COQ2  RARA  DHRS3  PTK2  CLEC4E  CXCR4  IL1A  C19ORF38  IL18BP   PTK2  TNFRSF21  EEPD1  SLC2A1  SLC44A2  SEMA6B  CLEC4E  PKIG  CD300A  TMEM135 P21  P38  P06  P12  P38  P15  P21  P15  P38  P21  P06  P12   T09   DMHCA   Des   C   D   MGLL  PLA2G7  CKB  LAT  CXCL2  IER3  FZD1  CYP27A1  FAM213B  GYPC  ATF3  JDP2  CTSK  EMP1  DUSP2  TSC22D1  PDGFB  TMEMM5B  FGL2  RGL1  CAMK1  TGFBI  ACOT7  TMEM256  CRIP1  ISOC2  OAZ2  EVL  GALM  LACC1  SEPP1  HES6  LPAR5  NUDT8  IGFBP4  IL7R  SLC38A2  SLC29A1  NR1H3   TIFAB  CXCL2  ATP1B1  TMEM97  HMGCS1  TM7SF2  C14ORF1  MVK  SC5D  HSD17B7  SQLE  HMGCR  CYP51A1  FDFT1  ACAT2  EBP  FDPS  DHCR7  INSIG1  MSMO1  MVD  LDLR  FADS2  FADS1  LPIN1  ALDOC  ACLY  AACS  LSS  DHCR24  PCYT2  NSDHL  MMAB  ACSS2  STARD4  TSC22D3  TUBA1A  VWF  PANK3  FASN  SCD  ABCG1  SMPDL3A  ABCA1  SDC3  SREBF1  CD82  CDCA7L  ARL4C  MYLIP  NEURL2  PLTP  LPCAT3  CFP  CXCR4  TRPV4  NR1H3  SLC29A1  ACVRL1  DHRS3  ABCD1  RARA  HPSE  COQ2   PLIN2  SEMA6B  PTGER2  TFPI  RAB20  IL1RN  TMCC3  PLAUR  HK2  SLC2A1  CD300A  EXT1  HPSE  GBP2  STOM  TNFRSF21  TRPV4  S1PR1  COQ2  RARA  DHRS3  PTK2  CLEC4E  CXCR4  IL1A  C19ORF38  IL18BP   PTK2  TNFRSF21  EEPD1  SLC2A1  SLC44A2  SEMA6B  CLEC4E  PKIG  CD300A  TMEM135 HMDM   0  12  10  8  6  4  2  0  12  10  8  6  4  2  0  12  10  8  6 
